US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4201860A
(en)
|
1978-05-09 |
1980-05-06 |
Bristol-Myers Company |
Purine derivatives
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
US4810646A
(en)
|
1984-11-28 |
1989-03-07 |
Massachusetts Institute Of Technology |
Glucan compositions and process for preparation thereof
|
US5082936A
(en)
|
1984-11-28 |
1992-01-21 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
US4992540A
(en)
|
1984-11-28 |
1991-02-12 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
US5028703A
(en)
|
1988-03-11 |
1991-07-02 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
DE3529497A1
(de)
|
1985-08-17 |
1987-02-26 |
Boehringer Mannheim Gmbh |
N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
DE3788914T2
(de)
|
1986-09-08 |
1994-08-25 |
Ajinomoto Kk |
Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
ZA902710B
(en)
|
1989-05-22 |
1991-12-24 |
Univ Georgia Res Found |
Enzyme luminescence assay
|
US5032401A
(en)
|
1989-06-15 |
1991-07-16 |
Alpha Beta Technology |
Glucan drug delivery system and adjuvant
|
WO1991003248A2
(en)
|
1989-09-08 |
1991-03-21 |
Alpha Beta Technology, Inc. |
Method for immune system activation
|
JPH05503952A
(ja)
|
1989-09-08 |
1993-06-24 |
アルファ ベータ テクノロジー,インコーポレイティッド |
可溶性グルカン類の製造方法
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
AU7579991A
(en)
|
1990-02-20 |
1991-09-18 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
WO1991017424A1
(en)
|
1990-05-03 |
1991-11-14 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
CA2040374C
(en)
|
1990-07-06 |
1998-06-16 |
Gunnar Rorstad |
Process for enhancing the resistance of aquatic animals to disease
|
JPH0813274B2
(ja)
|
1990-08-13 |
1996-02-14 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
|
EP0547142A1
(en)
|
1990-08-28 |
1993-06-23 |
Epoch Pharmaceuticals, Inc. |
Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
GB9022560D0
(en)
|
1990-10-17 |
1990-11-28 |
G B Biotechnology Limited |
Processing of waste
|
US5419966A
(en)
|
1991-06-10 |
1995-05-30 |
Microprobe Corporation |
Solid support for synthesis of 3'-tailed oligonucleotides
|
US5214135A
(en)
|
1991-08-30 |
1993-05-25 |
Chemgenes Corporation |
N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
|
US5525719A
(en)
|
1991-08-30 |
1996-06-11 |
Chemgenes Corporation |
N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
US5428149A
(en)
|
1993-06-14 |
1995-06-27 |
Washington State University Research Foundation |
Method for palladium catalyzed carbon-carbon coulping and products
|
US5580972A
(en)
|
1993-06-14 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
Purine nucleoside modifications by palladium catalyzed methods
|
US5652359A
(en)
|
1993-12-02 |
1997-07-29 |
Epoch Pharmaceuticals, Inc. |
Oligonucleotides containing n-methyl thiolated bases having antiviral activity
|
US5646126A
(en)
|
1994-02-28 |
1997-07-08 |
Epoch Pharmaceuticals |
Sterol modified oligonucleotide duplexes having anticancer activity
|
US5651981A
(en)
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
US5777153A
(en)
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
US5767099A
(en)
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
AUPN166195A0
(en)
|
1995-03-13 |
1995-04-06 |
Norvet Research Pty Limited |
Process for glucan extraction
|
JP4338106B2
(ja)
|
1995-06-07 |
2009-10-07 |
ライフ テクノロジーズ コーポレーション |
ペプチド増強カチオン脂質トランスフェクション
|
US5851548A
(en)
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
AUPN398295A0
(en)
|
1995-07-05 |
1995-07-27 |
Carlton And United Breweries Limited |
Chemical compounds and processes for their production
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
AU1507199A
(en)
|
1997-12-15 |
1999-07-05 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel pyrimidine-5-carboxamide derivatives
|
US6020483A
(en)
|
1998-09-25 |
2000-02-01 |
Nexstar Pharmaceuticals, Inc. |
Nucleoside modifications by palladium catalyzed methods
|
US8017742B2
(en)
|
1999-11-10 |
2011-09-13 |
Japan Science And Technology Agency |
Gene carrier
|
US20040072785A1
(en)
|
1999-11-23 |
2004-04-15 |
Wolff Jon A. |
Intravascular delivery of non-viral nucleic acid
|
US7098030B2
(en)
|
1999-12-31 |
2006-08-29 |
Mirus Bio Corporation |
Polyampholytes for delivering polyions to a cell
|
ES2346513T3
(es)
|
2000-07-24 |
2010-10-18 |
Krenitsky Pharmaceuticals, Inc. |
5-alquinil pirimidinas sustituidas que tienen actividad neurotrofica.
|
CA2418030C
(en)
|
2000-08-03 |
2010-10-26 |
Martin Sauter |
Isolation of glucan particles and uses thereof
|
US6476003B1
(en)
|
2000-11-06 |
2002-11-05 |
Immusonic, Inc. |
Method for preparing small particle size glucan in a dry material
|
FR2818642B1
(fr)
|
2000-12-26 |
2005-07-15 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
|
US7786094B2
(en)
|
2001-10-09 |
2010-08-31 |
Biopolymer Engineering, Inc. |
Use of beta-glucans against biological warfare weapons and pathogens including anthrax
|
WO2004033620A2
(en)
|
2001-11-02 |
2004-04-22 |
Insert Therapeutics, Inc. |
Methods and compositions for therapeutic use of rna interference
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
DE10302421A1
(de)
|
2003-01-21 |
2004-07-29 |
Ribopharma Ag |
Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
US20050026286A1
(en)
|
2003-03-05 |
2005-02-03 |
Jen-Tsan Chi |
Methods and compositions for selective RNAi mediated inhibition of gene expression in mammal cells
|
ES2702942T3
(es)
|
2003-04-17 |
2019-03-06 |
Alnylam Pharmaceuticals Inc |
Agentes de ARNi modificados
|
US20060178327A1
(en)
|
2003-05-30 |
2006-08-10 |
Yeung Wah Hin A |
Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
EP2567693B1
(en)
|
2003-07-16 |
2015-10-21 |
Protiva Biotherapeutics Inc. |
Lipid encapsulated interfering RNA
|
US20050265957A1
(en)
|
2004-04-08 |
2005-12-01 |
Monahan Sean D |
Polymerized formamides for use in delivery of compounds to cells
|
US10638750B2
(en)
|
2004-05-20 |
2020-05-05 |
Eden Research Plc |
Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
|
WO2005121348A1
(en)
|
2004-06-07 |
2005-12-22 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
US20090209624A1
(en)
|
2005-10-24 |
2009-08-20 |
University Of Massachusetts |
Compositions and their uses for gene therapy of bone conditions
|
US20070231392A1
(en)
|
2006-01-23 |
2007-10-04 |
Ernst Wagner |
CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY
|
AU2007278899B2
(en)
|
2006-06-23 |
2012-09-06 |
Engenelc Molecular Delivery Pty. Ltd. |
Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
|
US20080039415A1
(en)
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
JP5274461B2
(ja)
|
2006-08-18 |
2013-08-28 |
アローヘッド リサーチ コーポレイション |
ポリヌクレオチドのインビボ送達のためのポリ結合体
|
US8809514B2
(en)
|
2006-09-22 |
2014-08-19 |
Ge Healthcare Dharmacon, Inc. |
Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
US20090043367A1
(en)
|
2007-08-09 |
2009-02-12 |
Yitzhak Zilberman |
Apparatus and methods for removing an electronic implant from a body
|
EP2245039A4
(en)
|
2008-01-31 |
2012-06-06 |
Alnylam Pharmaceuticals Inc |
OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
|
CN104975020B
(zh)
|
2008-02-11 |
2020-01-17 |
菲奥医药公司 |
经修饰的RNAi多核苷酸及其用途
|
AU2009234266B2
(en)
|
2008-04-11 |
2015-08-06 |
Tekmira Pharmaceuticals Corporation |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
JP6209309B2
(ja)
|
2008-09-22 |
2017-10-04 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
サイズが減少した自己送達用RNAi化合物
|
BR112012029057A2
(pt)
*
|
2010-05-14 |
2020-10-13 |
Dana-Farber Cancer Institute, Inc. |
composições e métodos de tratamento de leucemia
|
US9006199B2
(en)
*
|
2011-11-14 |
2015-04-14 |
Silenseed Ltd. |
Methods and compositions for treating prostate cancer
|
WO2014076703A1
(en)
*
|
2012-11-14 |
2014-05-22 |
Silenseed Ltd. |
Methods and compositions for treating cancer
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|